Mednax, Inc (NYSE:MD) – Equities research analysts at KeyCorp decreased their Q3 2017 EPS estimates for Mednax in a research report issued on Sunday. KeyCorp analyst J. Gurda now expects that the company will earn $0.77 per share for the quarter, down from their prior estimate of $0.80. KeyCorp currently has a “Overweight” rating and a $51.00 target price on the stock. KeyCorp also issued estimates for Mednax’s Q4 2017 earnings at $0.79 EPS and FY2017 earnings at $3.06 EPS.
Mednax (NYSE:MD) last released its earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.04. The business had revenue of $843.00 million during the quarter, compared to the consensus estimate of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 earnings per share.
A number of other analysts have also commented on MD. Mizuho restated a “neutral” rating and set a $48.00 price target (down previously from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Jefferies Group LLC set a $46.00 price target on shares of Mednax and gave the company a “hold” rating in a research note on Sunday, July 30th. Stifel Nicolaus reduced their target price on shares of Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a research note on Thursday, May 25th. BidaskClub upgraded shares of Mednax from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th. Finally, ValuEngine lowered shares of Mednax from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $58.89.
Mednax (MD) opened at 41.19 on Tuesday. The company has a 50-day moving average of $43.21 and a 200-day moving average of $56.37. The company has a market cap of $3.80 billion, a P/E ratio of 13.12 and a beta of 0.40. Mednax has a 52-week low of $40.78 and a 52-week high of $72.13.
In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 2.40% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lord Abbett & CO. LLC bought a new position in Mednax during the second quarter valued at about $14,346,000. Tandem Investment Advisors Inc. grew its position in Mednax by 10.5% during the second quarter. Tandem Investment Advisors Inc. now owns 21,755 shares of the company’s stock valued at $1,313,000 after buying an additional 2,065 shares during the period. Verition Fund Management LLC bought a new position in Mednax during the second quarter valued at about $516,000. Grandeur Peak Global Advisors LLC grew its position in Mednax by 6.5% during the second quarter. Grandeur Peak Global Advisors LLC now owns 200,125 shares of the company’s stock valued at $12,082,000 after buying an additional 12,300 shares during the period. Finally, Sterling Capital Management LLC grew its position in Mednax by 2.4% during the second quarter. Sterling Capital Management LLC now owns 1,048,652 shares of the company’s stock valued at $63,307,000 after buying an additional 24,228 shares during the period.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.